AAAnn C. Anselme

Ann C. Anselme

*This is an algorithmically generated author record based on publicly available information.

Ann C. Anselme has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tumor-Intrinsic iNOS Drives Obesity-Associated Immune Suppression Through a CCL2-Dependent Myeloid Remodeling Program in Triple-Negative Breast Cancer

    by Ivonne D. Uzair, Agne Baseviciene, Jenying Deng, Recep Bayraktar, Ann C. Anselme, Laura C. Gomez, Wei Qian, Jianying Zhou, Kai Sun, Hong Zhao, et al.

    Obesity is associated with increased incidence and mortality in triple-negative breast cancer, however, the tumor-intrinsic mechanisms driving obesity-associated tumor progression remain poorly understood. Here, we identify the role of inducible nitric oxide synthase as a redox-active mediator that modulates obesity-associated inflammation and remodels the tumor microenvironment into an immunosuppressive state. iNOS expression was elevated in TNBC compared to other breast cancer subtypes and was associated with shorter overall survival, and obese TNBC patients preferentially benefited from iNOS inhibition combined with chemotherapy. In syngeneic TNBC models of diet-induced obesity, high-fat diet increased tumor growth and iNOS expression. Obesity-conditioned adipocytes induced tumor-cell iNOS expression and promoted iNOS-dependent production of the monocyte-recruiting chemokine CCL2. Tumor-specific deletion of iNOS abolished obesity-driven tumor progression and reprogrammed the tumor immune compartment by reducing recruitment of monocytic myeloid-derived suppressor cells, restoring antigen-presenting M1-like macrophages, and rescuing the tissue-resident memory-like cytotoxic T-cell population. Treatment with the pan-NOS inhibitor L-NMMA selectively enhanced the antitumor activity of docetaxel in obese, but not lean, tumor-bearing mice, and shifted the immune landscape of obese tumors toward that of lean controls. Together, these findings establish tumor-intrinsic iNOS as a key mediator of the obese tumor microenvironment through sustained nitric oxide signaling that promotes myeloid remodeling and impairs anti-tumor immunity. These results provide a strong rationale for clinical evaluation of iNOS-targeting strategies to enhance chemotherapy response, particularly in patients with obesity and TNBC.

  • Abstract 3991: NOS inhibition enhances docetaxel-mediated anti-tumor effect in obese mice with triple negative breast cancer

    by Ivonne Uzair, Kai Sun, Ann Anselme, Wei Qian, Jianying Zhou, Roberto Rosato, Jenny Chang

    Purpose of the study: To evaluate the role of obesity in tumor progression and tumor microenvironment (TME) dynamic after the inhibition of nitric oxide synthase (NOS) in syngeneic murine models engrafted with triple negative breast cancer (TNBC) tumors. For this study, we wanted to deepen the results of our recently completed phase I/II clinical trial, where treatment with NG-methyl-L-arginine (L-NMMA, a pan-NOS inhibitor) increased the response rate to chemotherapy (docetaxel) in obese metastatic TNBC (ER-/PR-/HER2-) patients to 86% vs. 60% in normal weight individuals. TME analysis from responders revealed a neutrophil phenotype shift from protumor N2 to antitumor N1. We thus hypothesize that combined treatment with L-NMMA and docetaxel enhances antitumor effect by modulating TME in obese mice with TNBC. Experimental procedures: 3-week old female C57BL/6 mice were fed for 10 weeks either with high fat diet (HFD) or normal diet (ND). At week 13, TNBC mouse E0771 tumor cells were injected into the mice mammary fat pad. Once tumors reached 100 mm3, the animals were randomized to four groups: vehicle; docetaxel; L-NMMA; and docetaxel plus L-NMMA treatment. Tumor volume was measured throughout the experiment and growth rate was compared between groups at the end of treatment. Blood, tumor and perigonadal white adipose tissue (pgWAT) were collected. Cytokines and nitrite/nitrate levels (NO2-/NO3-, a NO indicator) were measured from blood and conditioned media (CM) from pgWAT using appropriate kits. Tumor immune cell infiltration was evaluated by immunohistochemistry. GraphPad software was used for statistical analysis and P-values Citation Format: Ivonne Uzair, Kai Sun, Ann Anselme, Wei Qian, Jianying Zhou, Roberto Rosato, Jenny Chang. NOS inhibition enhances docetaxel-mediated anti-tumor effect in obese mice with triple negative breast cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3991.

  • Open Access

    Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6

    by Andrew W. Chung, Anthony J. Kozielski, Wei Qian, Jianying Zhou, Ann C. Anselme, Alfred A. Chan, Ping-Ying Pan, Delphine J. Lee, Jenny C. Chang

    Triple-negative breast cancer (TNBC) patients with mesenchymal stem-like (MSL) subtype have responded poorly to chemotherapy whereas patients with basal-like 1 (BL1) subtype achieved the best clinical response. In order to gain insight into pathways that may contribute to the divergent sensitivity to chemotherapy, we compared the inflammatory profile of the two TNBC subtypes treated with docetaxel. Cellular signaling analysis determined that docetaxel activated MAPK pathway in MSL TNBCs but not BL1 TNBCs. The subsequent MAPK pathway activation in MSL TNBCs led to an IL-1A mediated cascade of autocrine inflammatory mediators including IL-6. Utilizing the humanized IL-6R antibody, tocilizumab, our in vitro and in vivo data show that MSL TNBCs treated with tocilizumab together with chemotherapy results in delayed tumor progression compared to MSL TNBCs treated with docetaxel alone. Our study highlights a molecular subset of TNBC that may be responsive to tocilizumab therapy for potential translational impact.


  • A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer

    by Andrew W. Chung, Kartik Anand, Ann C. Anselme, Alfred A. Chan, Nakul Gupta, Luz A. Venta, Mary R. Schwartz, Wei Qian, Yitian Xu, Licheng Zhang, et al.

    A phase 1/2 clinical trial in patients with chemoresistant triple-negative breast cancer targets the inducible nitric oxide signaling pathway.


  • Open Access

    Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs

    by Tejaswini P. Reddy, Dong S. Choi, Ann C. Anselme, Wei Qian, Wen Chen, Johan Lantto, Ivan D. Horak, Michael Kragh, Jenny C. Chang, Roberto R. Rosato

    Background: The human epidermal growth factor receptor (HER) family, notably EGFR, is overexpressed in most triple-negative breast cancer (TNBC) cases and provides cancer cells with compensatory signals that greatly contribute to the survival and development of resistance in response to therapy. This study investigated the effects of Pan-HER (Symphogen, Ballerup, Denmark), a novel mixture of six monoclonal antibodies directed against members of the HER family EGFR, HER2, and HER3, in a preclinical trial of TNBC patient-derived xenografts (PDXs). Methods: Fifteen low passage TNBC PDX tumor samples were transferred into the right mammary fat pad of mice for engraftment. When tumors reached an average size of 100–200 mm3, mice were randomized (n ≥ 6 per group) and treated following three 1-week cycles consisting of three times/week intraperitoneal (IP) injection of either formulation buffer (vehicle control) or Pan-HER (50 mg/kg). At the end of treatment, tumors were collected for Western blot, RNA, and immunohistochemistry analyses. Results: All 15 TNBC PDXs were responsive to Pan-HER treatment, showing significant reductions in tumor growth consistent with Pan-HER-mediated tumor downmodulation of EGFR and HER3 protein levels and significantly decreased activation of associated HER family signaling pathways AKT and ERK. Tumor regression was observed in five of the models, which corresponded to those PDX tumor models with the highest level of HER family activation. Conclusions: The marked effect of Pan-HER in numerous HER family-dependent TNBC PDX models justifies further studies of Pan-HER in TNBC clinical trials as a potential therapeutic option.